Botulinum toxin type A + Placebo

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Cerebrovascular Accident

Conditions

Cerebrovascular Accident, Muscle Spasticity

Trial Timeline

Nov 1, 2004 → Jul 20, 2006

NCT ID

NCT00216411

About Botulinum toxin type A + Placebo

Botulinum toxin type A + Placebo is a approved stage product being developed by Ipsen for Cerebrovascular Accident. The current trial status is completed. This product is registered under clinical trial identifier NCT00216411. Target conditions include Cerebrovascular Accident, Muscle Spasticity.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03569098	Phase 2	Completed	Jun 19, 2018	May 22, 2020	Hallux Abducto Valgus
NCT03598777	Phase 2	Terminated	Jun 11, 2018	Jan 21, 2021	Vulvodynia
NCT02493946	Phase 3	Completed	Apr 1, 2015	Dec 1, 2016	Glabellar Lines
NCT02353871	Phase 3	Completed	Jan 1, 2015	Aug 1, 2015	Moderate to Severe Glabellar Lines
NCT02321436	Approved	Completed	Dec 1, 2014	Mar 1, 2016	Stroke
NCT01753310	Phase 3	Completed	Jan 1, 2013	Jan 1, 2015	Cervical Dystonia
NCT01249417	Phase 3	Completed	Jul 1, 2011	Jun 1, 2014	Cerebral Palsy
NCT01357980	Phase 2	Completed	May 1, 2011	Mar 1, 2013	Detrusor Muscle Hyperactivity
NCT01249404	Phase 3	Completed	Mar 1, 2011	May 1, 2014	Leg Spasticity
NCT00578097	Phase 2	Terminated	Feb 1, 2008	Dec 1, 2009	Overactive Bladder
NCT00257660	Phase 3	Completed	Oct 10, 2005	Sep 1, 2006	Cervical Dystonia
NCT00447876	Phase 2/3	Completed	Jul 1, 2005	Apr 1, 2009	Chronic Plantar Fasciitis
NCT00216411	Approved	Completed	Nov 1, 2004	Jul 20, 2006	Cerebrovascular Accident
NCT00234546	Approved	Completed	Feb 1, 2003	Oct 1, 2007	Muscle Spasticity

Competing Products

14 competing products in Cerebrovascular Accident

See all competitors

Product	Company	Stage	Hype Score
YM872 (zonampanel)	Astellas Pharma	Phase 2	52
donepezil hcl	Eisai	Phase 3	77
Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride	Eisai	Approved	85
ONO-2506	Ono Pharmaceutical	Phase 2/3	65
Abciximab	Eli Lilly	Phase 3	77
atomoxetine + Stimulants	Eli Lilly	Pre-clinical	23
ticagrelor + ASA + Placebo+ASA	AstraZeneca	Approved	85
Valsartan	Novartis	Pre-clinical	23
Atorvastatin	Pfizer	Approved	84
Rivaroxaban	Bayer	Pre-clinical	20
Darolutamide (BAY1841788) + Enzalutamide	Bayer	Phase 1	30
Atorvastatin 20mg	Brain Biotech	Approved	77
Autologous bone marrow mononuclear cell transplantation	Brain Biotech	Phase 1	25
Roflumilast Oral Tablet	Brain Biotech	Phase 2	44

Other Products from Ipsen

AbobotulinumtoxinA + PlaceboApproved

lanreotide acetateApproved

Tigan® + PlaceboApproved

Diosmectite (Smecta®)Approved

lanreotide (Autogel formulation)Approved